Open AccessOral mucormycosis in post-COVID-19 patients: A case series
Author(s) -
Shamli Sadawarte Dr. Shamli Sadawarte,
Neha N. Kharwade Kharwade,
Sayojyata S. Bangar. Bangar.,
Mangala R. Dr. Mangala R.,
Swati Paraye. Paraye.,
Sam Ponraj Davidson. S
Publication year - 2022
Publication title -
indian journal of case reports
Language(s) - English
Resource type - Journals
eISSN - 2454-1303
pISSN - 2454-129X
DOI - 10.32677/ijcr.v8i2.3258
Subject(s) - mucormycosis , medicine , neutropenia , covid-19 , intensive care unit , pandemic , diabetes mellitus , dermatology , immunosuppression , intensive care medicine , surgery , infectious disease (medical specialty) , disease , toxicity , endocrinology
The rise of mucormycosis in COVID-19 patients is predisposed by indiscriminate intake of corticosteroids, poorly controlled diabetes, injury, the prolonged neutropenia, organ transplant, hemopoietic malignancies, prolonged stays in the intensive care unit and due to nosocomial infection (Raut &Huy, 2021).Oral lesions seen in COVID-19 patients are more probably caused by co-infections, adverse reactions, immunocompromised conditions instead of direct COVID-19 infection. Not every mucormycosis that occurs in the pandemic times is due to COVID-19.We would like to report 4 post-COVID-19 patients who had oral mucormycosis after covid recovery period.